Clinical and Molecular Features of Type 1 Pseudohypoaldosteronism

Hormone Research

Volumn 72, Issue 1, 2009, Pages 1-9

  Riepe, Felix G ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Aldosterone; Epithelial sodium channel; Mineralocorticoid receptor; Pseudohypoaldosteronism; Salt loss

Indexed keywords

EPITHELIAL SODIUM CHANNEL; EPITHELIAL SODIUM CHANNEL ALPHA; EPITHELIAL SODIUM CHANNEL BETA; EPITHELIAL SODIUM CHANNEL GAMMA; MINERALOCORTICOID; MINERALOCORTICOID RECEPTOR; SODIUM; UNCLASSIFIED DRUG;

CLINICAL FEATURE; DEHYDRATION; FAILURE TO THRIVE; FRAMESHIFT MUTATION; GENETIC HETEROGENEITY; GENOTYPE PHENOTYPE CORRELATION; GORDON SYNDROME; HORMONE RESISTANCE; KIDNEY DISEASE; MISSENSE MUTATION; NONHUMAN; NONSENSE MUTATION; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTON TRANSPORT; PSEUDOHYPOALDOSTERONISM; SHOCK; SHORT SURVEY; SODIUM ABSORPTION; SODIUM DEPLETION;

ALDOSTERONE; EPITHELIAL CELLS; EPITHELIAL SODIUM CHANNEL; GENOTYPE; HUMANS; INFANT; MODELS, MOLECULAR; MUTATION; PHENOTYPE; PSEUDOHYPOALDOSTERONISM; RECEPTORS, MINERALOCORTICOID;

EID: 67651092155     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000224334     Document Type: Short Survey

References (63)

1. Arriza JL, Weinberger C, Cerelli G, Glaser TM, Handelin BL, Housman DE, Evans RM: Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987;237:268-275.
2. Zennaro MC, Farman N, Bonvalet JP, Lombes M: Tissue-specific expression of α and β messenger ribonucleic acid isoforms of the human mineralocorticoid receptor in normal and pathological states. J Clin Endocrinol Metab 1997;82:1345-1352.
3. Zennaro MC, Le Menuet D, Lombes M: Characterization of the human mineralocorticoid receptor gene 5′-regulatory region: evidence for differential hormonal regulation of two alternative promoters via non-classical mechanisms. Mol Endocrinol 1996;10:1549-1560.
4. Pascual-Le Tallec L, Lombes M: The mineralocorticoid receptor: a journey exploring its diversity and specificity of action. Mol Endocrinol 2005;19:2211-2221.
5. Seeler JS, Dejean A: Nuclear and unclear functions of sumo. Nat Rev Mol Cell Biol 2003;4:690-699.
6. Rogerson FM, Fuller PJ: Interdomain interactions in the mineralocorticoid receptor. Mol Cell Endocrinol 2003;200:45-55.
7. Fagart J, Huyet J, Pinon GM, Rochel M, Mayer C, Rafestin-Oblin ME: Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension. Nat Struct Mol Biol 2005;12:554-555.
8. Bledsoe RK, Madauss KP, Holt JA, Apolito CJ, Lambert MH, Pearce KH, Stanley TB, Stewart EL, Trump RP, Willson TM, Williams SP: A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor. J Biol Chem 2005;280:31283-31293.
9. Li Y, Suino K, Daugherty J, Xu HE: Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol Cell 2005;19:367-380.
10. Garty H, Palmer LG: Epithelial sodium channels: function, structure, and regulation. Physiol Rev 1997;77:359-396.
11. + channel is made of three homologous subunits. Nature 1994;367:463-467.
12. Jasti J, Furukawa H, Gonzales EB, Gouaux E: Structure of acid-sensing ion channel 1 at 1.9 Å resolution and low pH. Nature 2007;449:316-323.
13. + channel subunit stoichiometry from single-channel conductances. J Gen Physiol 2007;130:55-70.
14. + channel (ENaC) by ubiquitination. EMBO J 1997;16:6325-6336.
15. Shimkets RA, Warnock DG, Bositis CM, Nelson-Williams C, Hansson JH, Schambelan M, Gill JR Jr, Ulick S, Milora RV, Findling JW, et al: Liddle's syndrome: heritable human hypertension caused by mutations in the β-subunit of the epithelial sodium channel. Cell 1994;79:407-414. (This study delineates activating mutations in the carboxy-terminal region of the ENaC β-subunit as cause for Liddle's syndrome, an autosomal dominant form of hypertension.)
16. + channel (α rENaC) mediates its localization at the apical membrane. EMBO J 1994;13:4440-4450.
17. Pearce D, Bhargava A, Cole TJ: Aldosterone: its receptor, target genes, and actions. Vitam Horm 2003;66:29-76.
18. Fuller PJ, Young MJ: Mechanisms of mineralocorticoid action. Hypertension 2005;46:1227-1235.
19. Ratajczak T, Ward BK, Minchin RF: Immu-nophilin chaperones in steroid receptor signalling. Curr Top Med Chem 2003;3:1348-1357.
20. Hellal-Levy C, Fagart J, Souque A, Rafestin-Oblin ME: Mechanistic aspects of mineralocorticoid receptor activation. Kidney Int 2000;57:1250-1255.
21. Fejes-Toth G, Pearce D, Naray-Fejes-Toth A: Subcellular localization of mineralocorticoid receptors in living cells: effects of receptor agonists and antagonists. Proc Natl Acad Sci USA 1998;95:2973-2978.
22. Robert-Nicoud M, Flahaut M, Elalouf JM, Nicod M, Salinas M, Bens M, Doucet A, Wincker P, Artiguenave F, Horisberger JD, Vandewalle A, Rossier BC, Firsov D: Tran-scriptome of a mouse kidney cortical collecting duct cell line: effects of aldosterone and vasopressin. Proc Natl Acad Sci USA 2001;98:2712-2716.
23. Pearce D: Sgk1 regulation of epithelial sodium transport. Cell Physiol Biochem 2003;13:13-20.
24. Bhalla V, Daidie D, Li H, Pao AC, LaGrange LP, Wang J, Vandewalle A, Stockand JD, Staub O, Pearce D: Serum- and glucocorticoid-regulated kinase 1 regulates ubiquitin ligase neural precursor cell-expressed, developmentally down-regulated protein 4-2 by inducing interaction with 14-3-3. Mol Endocrinol 2005;19:3073-3084.
25. Snyder PM, Steines JC, Olson DR: Relative contribution of Nedd4 and Nedd4-2 to ENaC regulation in epithelia determined by RNA interference. J Biol Chem 2004;279:5042-5046.
26. Mick VE, Itani OA, Loftus RW, Husted RF, Schmidt TJ, Thomas CP: The α-subunit of the epithelial sodium channel is an aldoste-rone-induced transcript in mammalian collecting ducts, and this transcriptional response is mediated via distinct cis -elements in the 5′-flanking region of the gene. Mol Endocrinol 2001;15:575-588.
27. Yoo D, Kim BY, Campo C, Nance L, King A, Maouyo D, Welling PA: Cell surface expression of the ROMK (Kir-1.1) channel is regulated by the aldosterone-induced kinase, SGK-1, and protein kinase A. J Biol Chem 2003;278:23066-23075.
28. Kuhnle U: Pseudohypoaldosteronism: mutation found, problem solved? Mol Cell Endocrinol 1997;133:77-80.
29. Gordon RD: Syndrome of hypertension and hyperkalemia with normal glomerular filtration rate. Hypertension 1986;8:93-102.
30. Wilson FH, Disse-Nicodeme S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford DV, Lipkin GW, Achard JM, Feely MP, Dussol B, Berland Y, Unwin RJ, Mayan H, Simon DB, Farfel Z, Jeunemai-tre X, Lifton RP: Human hypertension caused by mutations in WNK kinases. Science 2001;293:1107-1112.
31. Kahle KT, Wilson FH, Lifton RP: Regulation of diverse ion transport pathways by WNK4 kinase: a novel molecular switch. Trends Endocrinol Metab 2005;16:98-103.
32. Xie J, Craig L, Cobb MH, Huang CL: Role of with-no-lysine [K] kinases in the pathogenesis of Gordon's syndrome. Pediatr Nephrol 2006;21:1231-1236.
33. Subramanya AR, Yang CL, McCormick JA, Ellison DH: WNK kinases regulate sodium chloride and potassium transport by the al-dosterone-sensitive distal nephron. Kidney Int 2006;70:630-634.
34. Disse-Nicodeme S, Achard JM, Desitter I, Houot AM, Fournier A, Corvol P, Jeunemai-tre X: A new locus on chromosome 12p13.3 for pseudohypoaldosteronism type II, an autosomal dominant form of hypertension. Am J Hum Genet 2000;67:302-310.
35. Bulchmann G, Schuster T, Heger A, Kuhnle U, Joppich I, Schmidt H: Transient pseudohypoaldosteronism secondary to posterior urethral valves - a case report and review of the literature. Eur J Pediatr Surg 2001;11:277-279.
36. Maruyama K, Watanabe H, Onigata K: Reversible secondary pseudohypoaldosteronism due to pyelonephritis. Pediatr Nephrol 2002;17:1069-1070.
37. Dolezel Z, Starha J, Novotna D, Dostalkova D: Secondary pseudohypoaldosteronism in an infant with pyelonephritis. Bratisl Lek Listy 2004;105:435-437.
38. Perez-Brayfield MR, Gatti J, Smith E, Kirsch AJ: Pseudohypoaldosteronism associated with ureterocele and upper pole moiety obstruction. Urology 2001;57:1178.
39. Cheek D, Perry J: A salt-wasting syndrome in infancy. Arch Dis Chi ld 1958;33:252-256.
40. Geller DS: Mineralocorticoid resistance. Clin Endocrinol (Ox f ) 2005;62:513-520.
41. Geller DS, Rodriguez-Soriano J, Vallo Boado A, Schifter S, Bayer M, Chang SS, Lifton RP: Mutations in the mineralocorticoid receptor gene cause autosomal dominant pseudohy-poaldosteronism type 1. Nat Genet 1998;19:279-281. (First report on NR3C2 mutations in adPHA1.)
42. Kuhnle U, Nielsen MD, Tietze HU, Schroeter CH, Schlamp D, Bosson D, Knorr D, Arma-nini D: Pseudohypoaldosteronism in eight families: different forms of inheritance are evidence for various genetic defects. J Clin Endocrinol Metab 1990;70:638-641.
43. Riepe FG, Finkeldei J, de Sanctis L, Einaudi S, Testa A, Karges B, Peter M, Viemann M, Grotzinger J, Sippell WG, Fejes-Toth G, Krone N: Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing au-tosomal dominant pseudohypoaldosteron-ism type 1. J Clin Endocrinol Metab 2006;91:4552-4561.
44. Geller DS, Zhang J, Zennaro MC, Vallo-Boa-do A, Rodriguez-Soriano J, Furu L, Haws R, Metzger D, Botelho B, Karaviti L, Haqq AM, Corey H, Janssens S , Corvol P, Lifton RP: Autosomal dominant pseudohypoaldosteronism type 1:mechanisms, evidence for neonatal lethality, and phenotypic expression in adults. J Am Soc Nephrol 2006;17:1429-1436.
45. Riepe FG, Krone N, Morlot M, Peter M, Sippell WG, Partsch CJ: Autosomal-dominant pseudohypoaldosteronism type 1 in a Turkish family is associated with a novel nonsense mutation in the human mineralocorticoid receptor gene. J Clin Endocrinol Metab 2004;89:2150-2152.
46. Couette B, Jalaguier S, Hellal-Levy C, Lupo B, Fagart J, Auzou G, Rafestin-Oblin ME: Folding requirements of the ligand-binding domain of the human mineralocorticoid receptor. Mol Endocrinol 1998;12:855-863.
47. Pujo L, Fagart J, Gary F, Papadimitriou DT, Claes A, Jeunemaitre X, Zennaro MC: Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoa ldosteronism. Hum Mutat 2007;28:33-40.
48. Balsamo A, Cicognani A, Gennari M, Sippell WG, Menabo S, Baronio F, Riepe FG: Functional characterization of naturally occurring NR3C2 gene mutations in Italian patients suffering from pseudohypoaldosteronism type 1. Eur J Endocrinol 2007;156:249-256.
49. Sartorato P, Lapeyraque AL, Armanini D, Kuhnle U, Khaldi Y, Salomon R, Abadie V, Di Battista E, Naselli A, Racine A, Bosio M, Caprio M, Poulet-Young V, Chabrolle JP, Niaudet P, De Gennes C, Lecornec MH, Poisson E, Fusco AM, Loli P, Lombes M, Zennaro MC: Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type 1 pseudohypoaldosteronism. J Clin Endocrinol Metab 2003;88:2508-2517.
50. Kerem E, Bistritzer T, Hanukoglu A, Hofmann T, Zhou Z, Bennett W, MacLaughlin E, Barker P, Nash M, Quittell L, Boucher R Knowles MR: Pulmonary epithelial sodiumchannel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999;341:156-162.
51. Hanukoglu A, Bistritzer T, Rakover Y, Man-delberg A: Pseudohypoaldosteronism with increased sweat and saliva electrolyte values and frequent lower respiratory tract infections mimicking cystic fibrosis. J Pediatr 1994;125:752-755.
52. Marthinsen L, Kornfalt R, Aili M, Anders-son D, Westgren U, Schaedel C: Recurrent pseudomonas bronchopneumonia and other symptoms as in cystic fibrosis in a child with type I pseudohypoaldosteronism. Acta Pae-diatr 1998;87:472-474.
53. Schaedel C, Marthinsen L, Kristoffersson AC, Kornfalt R, Nilsson KO, Orlenius B, Holmberg L: Lung symptoms in pseudohypoaldosteronism type 1 are associated with deficiency of the α-subunit of the epithelial sodium channel. J Pediatr 1999;135:739-745.
54. Hanaki K, Ohzeki T, Iitsuka T, Nagata I, Urashima H, Tsukuda T, Nagaishi J, Shiraki K, Shimizu N, Kaibara N: An infant with pseudohypoaldosteronism accompanied by cholelithiasis. Biol Neonate 1994;65:85-88.
55. Martin JM, Calduch L, Monteagudo C, Alonso V, Garcia L, Jorda E: Clinico-pathological analysis of the cutaneous lesions of a patient with type 1 pseudohypoaldosteronism. J Eur Acad Dermatol Venereol 2005;19:377-379.
56. Wong GP, Levine D: Congenital pseudohypoaldosteronism presenting in utero with acute polyhydramnios. J Matern Fetal Med 1998;7:76-78.
57. Zennaro MC, Lombes M: Mineralocorticoid resistance. Trends Endocrinol Metab 2004;15:264-270.
58. Chang SS, Grunder S, Hanukoglu A, Rosler A, Mathew PM, Hanukoglu I, Schild L, Lu Y, Shimkets RA, Nelson-Williams C, Rossier BC, Lifton RP: Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996;12:248-253. (First report on SCNN1 mutations in ar-PHA1.)
59. Grunder S, Firsov D, Chang SS, Jaeger NF, Gautschi I, Schild L, Lifton RP, Rossier BC: A mutation causing pseudohypoaldosteronism type 1 identifies a conserved glycine that is involved in the gating of the epithelial sodium channel. EMBO J 1997;16:899-907.
60. + channel changes ion selectivity by modifying molecular sieving. Proc Natl Acad Sci USA 1999;96:4170-4175.
61. + channel. J Gen Physiol 1999;114:13-30.
62. Hummler E, Barker P, Gatzy J, Beermann F, Verdumo C, Schmidt A, Boucher R, Rossier BC: Early death due to defective neonatal lung liquid clearance in α-EnAC-deficient mice. Nat Genet 1996;12:325-328.
63. Hanukoglu A, Edelheit O, Shriki Y, Gizewska M, Dascal N, Hanukoglu I: Renin-aldosterone response, urinary Na/K ratio and growth in pseudohypoaldosteronism patients with mutations in epithelial sodium channel (EnAC) subunit genes. J Steroid Biochem Mol Biol 2008;111:268-274.